<b> U.S. ATryn Development Timeline </b> [Updated based on 1Q08 CC.] Jun 2008: Announce US partnership for HD indication and AD indication(s). Jul/Aug 2008: Complete BLA submission. Sep/Oct 2008: FDA decision on priority review (approximately 60 days after BLA submission). Jan/Feb 2009: FDA decision on BLA (assuming a six-month priority review).